NO20082182L - Sammensetninger og fremgangsmater for modulering av hemostase - Google Patents

Sammensetninger og fremgangsmater for modulering av hemostase

Info

Publication number
NO20082182L
NO20082182L NO20082182A NO20082182A NO20082182L NO 20082182 L NO20082182 L NO 20082182L NO 20082182 A NO20082182 A NO 20082182A NO 20082182 A NO20082182 A NO 20082182A NO 20082182 L NO20082182 L NO 20082182L
Authority
NO
Norway
Prior art keywords
methods
compositions
modulating hemostasis
hemostasis
modulating
Prior art date
Application number
NO20082182A
Other languages
English (en)
Other versions
NO345177B1 (no
Inventor
Rodney M Camire
Original Assignee
Philadelphia Children Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philadelphia Children Hospital filed Critical Philadelphia Children Hospital
Publication of NO20082182L publication Critical patent/NO20082182L/no
Publication of NO345177B1 publication Critical patent/NO345177B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Faktor Xa-varianter og fremgangsmåter for anvendelse derav er beskrevet
NO20082182A 2005-11-15 2008-05-13 Sammensetninger og fremgangsmåter for modulering av hemostase NO345177B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73668005P 2005-11-15 2005-11-15
PCT/US2006/060927 WO2007059513A2 (en) 2005-11-15 2006-11-15 Compositions and methods for modulating hemostasis

Publications (2)

Publication Number Publication Date
NO20082182L true NO20082182L (no) 2008-07-30
NO345177B1 NO345177B1 (no) 2020-10-26

Family

ID=38049397

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20082182A NO345177B1 (no) 2005-11-15 2008-05-13 Sammensetninger og fremgangsmåter for modulering av hemostase
NO20200671A NO20200671A1 (no) 2005-11-15 2020-06-05 Sammensetninger og fremgangsmåter for modulering av hemostase
NO20200670A NO20200670A1 (no) 2005-11-15 2020-06-05 Sammensetninger og fremgangsmåter for modulering av hemostase

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20200671A NO20200671A1 (no) 2005-11-15 2020-06-05 Sammensetninger og fremgangsmåter for modulering av hemostase
NO20200670A NO20200670A1 (no) 2005-11-15 2020-06-05 Sammensetninger og fremgangsmåter for modulering av hemostase

Country Status (26)

Country Link
US (4) US8383386B2 (no)
EP (4) EP1948690B1 (no)
JP (4) JP5823088B2 (no)
KR (4) KR101600158B1 (no)
CN (1) CN101356192B (no)
AU (1) AU2006315175B2 (no)
BR (1) BRPI0618654B1 (no)
CA (2) CA2629491C (no)
CR (1) CR9956A (no)
DK (1) DK1948690T3 (no)
EC (1) ECSP088452A (no)
ES (2) ES2496567T3 (no)
GT (1) GT200800065A (no)
HK (2) HK1128699A1 (no)
IL (1) IL191310A (no)
MX (3) MX2008006313A (no)
MY (1) MY162181A (no)
NO (3) NO345177B1 (no)
NZ (1) NZ568108A (no)
PL (1) PL1948690T3 (no)
PT (1) PT1948690E (no)
RU (2) RU2008123398A (no)
SI (1) SI1948690T1 (no)
SV (1) SV2008002906A (no)
WO (1) WO2007059513A2 (no)
ZA (1) ZA200804026B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268783B2 (en) 2007-09-28 2012-09-18 Portola Pharmaceuticals, Inc. Antidotes for factor Xa inhibitors and methods of using the same
CA2697583C (en) 2007-09-28 2016-04-12 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
CA2743496C (en) 2008-11-14 2018-03-27 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
CA2767858C (en) 2009-07-15 2019-02-12 Portola Pharmaceuticals, Inc. Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same
DK2624859T3 (en) 2010-10-06 2017-06-06 Medimmune Ltd FACTOR II ALONE OR IN COMBINATION WITH OTHER FACTORS FOR TREATMENT OF REDUCED HEMOSTASE IN CONNECTION WITH DILUTION COAGULOPATHY
EP2760887A4 (en) * 2011-09-30 2015-06-10 Philadelphia Children Hospital COMPOSITIONS AND METHODS OF HEMOSTASE MODULATION
MX365612B (es) * 2012-07-25 2019-06-07 Catalyst Biosciences Inc Polipeptidos de factor x modificados y usos de los mismos.
ES2761730T3 (es) 2013-01-31 2020-05-20 Pfizer Composiciones y procedimientos para contrarrestar la inhibición del factor Xa
FR3001729B1 (fr) * 2013-02-04 2015-03-06 Lab Francais Du Fractionnement Mutants du facteur x
EP3049434A1 (en) * 2013-09-24 2016-08-03 Pfizer Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
CA2928762A1 (en) * 2013-11-01 2015-05-07 The Children's Hospital Of Philadelphia Compositions and methods for increasing the half-life of factor xa
ES2772802T3 (es) * 2014-01-24 2020-07-08 Pfizer Composiciones y procedimientos para tratar la hemorragia intracerebral
BR112016027649A2 (pt) 2014-05-26 2017-08-15 Academisch Ziekenhuis Leiden Proteínas prohemostáticas para o tratamento de hemorragia
US10676731B2 (en) 2014-08-19 2020-06-09 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor IX function
CN109789181A (zh) 2016-07-27 2019-05-21 费城儿童医院 用于调节因子ix功能的组合物和方法
WO2023118150A1 (en) 2021-12-22 2023-06-29 Royal College Of Surgeons In Ireland A conjugate for use in localising a molecule to the vascular endothelium.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093699A (en) 1987-07-09 2000-07-25 The University Of Manitoba Method for gene therapy involving suppression of an immune response
WO1994017810A1 (en) 1993-02-12 1994-08-18 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
WO1994023744A1 (en) 1993-04-16 1994-10-27 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
WO1995005864A1 (en) 1993-08-27 1995-03-02 Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Convection-enhanced drug delivery
AT401270B (de) 1994-09-26 1996-07-25 Immuno Ag Verfahren zur quantifizierung von genomischer dna
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
CN100569297C (zh) 1995-02-28 2009-12-16 加利福尼亚大学董事会 基因转移介导的血管形成疗法
US6228646B1 (en) 1996-03-07 2001-05-08 The Regents Of The University Of California Helper-free, totally defective adenovirus for gene therapy
AT405517B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
AT405516B (de) * 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
AT410216B (de) * 1999-08-10 2003-03-25 Baxter Ag Faktor x-analogon mit verbesserter aktivierbarkeit
AU2001249389A1 (en) * 2000-03-22 2001-10-03 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
FR2831170B1 (fr) * 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
FR2841904B1 (fr) * 2002-07-03 2004-08-20 Inst Nat Sante Rech Med Analogues de facteurs x clivables par la thrombine
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
WO2010070137A1 (en) * 2008-12-19 2010-06-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Serine protease derivatives and uses in the prevention or the treatment of blood coagulation disorders

Also Published As

Publication number Publication date
WO2007059513A3 (en) 2007-11-29
KR20160029135A (ko) 2016-03-14
EP2431390A1 (en) 2012-03-21
US20090175931A1 (en) 2009-07-09
BRPI0618654B1 (pt) 2021-10-19
NO20200671A1 (no) 2008-07-30
KR101827569B1 (ko) 2018-02-09
JP2009515559A (ja) 2009-04-16
EP1948690A2 (en) 2008-07-30
AU2006315175B2 (en) 2013-02-07
ECSP088452A (es) 2008-07-30
CR9956A (es) 2008-08-21
PT1948690E (pt) 2014-09-08
EP2431390B1 (en) 2015-08-12
EP1948690A4 (en) 2009-06-17
EP1948690B1 (en) 2014-06-11
US9896676B2 (en) 2018-02-20
SI1948690T1 (sl) 2014-09-30
SV2008002906A (es) 2008-10-22
KR20140115374A (ko) 2014-09-30
US20180251745A1 (en) 2018-09-06
MX337059B (es) 2016-02-09
NO20200670A1 (no) 2008-07-30
KR20080078664A (ko) 2008-08-27
HK1165444A1 (zh) 2012-10-05
ES2549929T3 (es) 2015-11-03
JP5823088B2 (ja) 2015-11-25
US20160362673A1 (en) 2016-12-15
US9410137B2 (en) 2016-08-09
JP2018033459A (ja) 2018-03-08
CA2971971A1 (en) 2007-05-24
JP6236194B2 (ja) 2017-11-22
BRPI0618654A2 (pt) 2011-09-06
JP5957167B2 (ja) 2016-07-27
MY162181A (en) 2017-05-31
JP6571735B2 (ja) 2019-09-04
CN101356192A (zh) 2009-01-28
NZ568108A (en) 2011-09-30
US8383386B2 (en) 2013-02-26
US20140120155A1 (en) 2014-05-01
MX2008006313A (es) 2008-11-06
EP2423224B1 (en) 2015-08-12
ES2496567T3 (es) 2014-09-19
JP2016005464A (ja) 2016-01-14
RU2570547C2 (ru) 2015-12-10
CA2629491A1 (en) 2007-05-24
GT200800065A (es) 2008-11-03
DK1948690T3 (da) 2014-09-01
RU2008123398A (ru) 2009-12-27
AU2006315175A1 (en) 2007-05-24
MX336958B (es) 2016-02-05
CA2629491C (en) 2019-05-07
CN101356192B (zh) 2013-09-11
EP2423224A1 (en) 2012-02-29
BRPI0618654A8 (pt) 2019-01-15
PL1948690T3 (pl) 2014-11-28
NO345177B1 (no) 2020-10-26
JP2014073127A (ja) 2014-04-24
EP2431389A1 (en) 2012-03-21
WO2007059513A2 (en) 2007-05-24
KR101574042B1 (ko) 2015-12-03
ZA200804026B (en) 2009-10-28
HK1128699A1 (en) 2009-11-06
KR20140005383A (ko) 2014-01-14
IL191310A (en) 2015-06-30
RU2011130932A (ru) 2013-01-27
KR101600158B1 (ko) 2016-03-08

Similar Documents

Publication Publication Date Title
NO20082182L (no) Sammensetninger og fremgangsmater for modulering av hemostase
AU2016204344A1 (en) Improved methods and compositions for wound healing
CY1117833T1 (el) Νεες συνθεσεις και μεθοδοι για την αγωγη του καρκινου
HUS1700042I1 (hu) SMN2-Splicing módosítására szolgáló készítmények és eljárások
DK1877390T3 (da) Benzisoxazol-piperazin-forbindelser og fremgangsmåder til anvendelse deraf
NO20092637L (no) Fremgangsmater for behandling
ATE471324T1 (de) Triazolophthalazine
MX2007008137A (es) Triazoloftalazinas como inhibidores de pde2.
PH12014500053A1 (en) Proteasome inhibitors
NO20070130L (no) Farmasoytiske sammensetninger
DE602007013440D1 (de) Substituierte indole
NO20084334L (no) Farmasoytiske sammensetninger
EA200800321A1 (ru) Ингибиторы гистондеацетилазы
CY1113102T1 (el) Ενωσεις φαινυλπροπιοναμιδιου και η χρηση αυτων
NO20090994L (no) 2-aminobenzoxazol karboxamider som 5HT3 modulatorer
NO20072302L (no) Modulatorer av hepatocyttvekstfaktoraktivator
EP1963513A4 (en) ALLERGY INHIBITOR COMPOSITIONS AND KITS AND METHODS OF USING SAME
HK1142608A1 (en) 5-pyridinone substituted indazoles and pharmaceutical compositions thereof 5-
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
CY1110036T1 (el) Μεθοδος συνθεσης του ρανελικου στροντιου και των ενυδρων αλατων του
MA32474B1 (fr) Nouveaux derives de (piperazinyl ponte) -1-alcanone et leur utilisation comme inhibiteurs de p75
MX2008002804A (es) Formas cristalinas de atorvastatina.
CY1123986T1 (el) Νεες συνθεσεις και μεθοδοι για τη θεραπεια του καρκινου